Carbohydrate metabolism during growth hormone treatment and after discontinuation of growth hormone treatment in girls with Turner syndrome treated with once or twice daily growth hormone injections

被引:17
|
作者
Sas, T
de Muinck Keizer-Schrama, S
Aanstoot, HJ
Stijnen, T
Drop, S
机构
[1] Sophia Childrens Univ Hosp, Dept Paediat, Div Endocrinol, NL-3015 GJ Rotterdam, Netherlands
[2] Erasmus Univ, Dept Epidemiol & Biostat, NL-3000 DR Rotterdam, Netherlands
[3] IJsselland Hosp, Dept Paediat, Capelle, Netherlands
关键词
D O I
10.1046/j.1365-2265.2000.01007.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVE To assess possible side-effects of treatment with supraphysiological GH dosages on carbohydrate (CH) metabolism in girls with Turner syndrome (TS) during GH treatment until adult height is reached as well as after discontinuation of GH treatment. DESIGN In a prospective, randomized injection frequency-response study, the effect of GH treatment in combination with low dose ethinyl oestradiol on CH metabolism was evaluated, comparing twice daily (BID) with once daily (OD) injections of a total GH dose of 6 U/m(2)/day until adult height was reached. PATIENTS Nineteen untreated girls with TS, mean (SD) pretreatment age 13.3 (1.7) (range 11.0-17.6) year. MEASUREMENTS Glucose and insulin concentrations during oral glucose tolerance tests (OGTT) were measured before and during GH treatment, as well as at 6 months after discontinuation of GH treatment. RESULTS GH treatment was discontinued after a mean of 43 (range 27-57) months. In one of the 19 girls, a different girl at each time point before, during and after discontinuation of GH treatment, the glucose response to OGTT after 120 minutes was above 7.8 mmol/l but below 11.1 mmol/l, indicating impaired glucose tolerance. None of the girls developed diabetes mellitus. Fasting glucose levels did not significantly change during, or after discontinuation of GH treatment. The 3 h area under the curve for time-concentration adjusted for fasting levels during the OGTT for glucose showed a significant decrease during GH treatment. In contrast to the glucose levels, GH treatment induced considerably higher insulin levels compared to pretreatment values. After discontinuation of GH insulin levels decreased to values comparable with pretreatment levels. None of these observed changes were different between the GH injection frequency groups. The changes in CH variables during and after discontinuation of GH were not related to changes in body mass index. CONCLUSIONS GH treatment with 6 U/m(2)/day in combination with low dose ethinyl oestradiol in girls with Turner syndrome aged greater than or equal to 11 years did not negatively influence glucose levels, but induced higher levels of insulin indicating relative insulin resistance. These changes in insulin levels were independent of the frequency of the GH injections (once vs. twice daily). After discontinuation of GH treatment, insulin values decreased to baseline levels.
引用
收藏
页码:741 / 747
页数:7
相关论文
共 50 条
  • [1] Final height in girls with Turner's syndrome treated with once or twice daily growth hormone injections
    Sas, TCJ
    Keizer-Schrama, SMPFD
    Stijnen, T
    van Teunenbroek, A
    Hokken-Koelega, ACS
    Waelkens, JJJ
    Massa, GG
    Vulsma, T
    Gerver, WJ
    Reeser, HM
    Delemarre-van de Waal, HE
    Jansen, M
    Drop, SLS
    ARCHIVES OF DISEASE IN CHILDHOOD, 1999, 80 (01) : 36 - 41
  • [2] Growth response and levels of growth factors after two years growth hormone treatment are similar for a once and twice daily injection regimen in girls with Turner syndrome
    vanTeunenbroek, A
    KeizerSchrama, SD
    Stijnen, T
    Waelkens, J
    Wit, JM
    Vulsma, T
    Gerver, WJ
    Reeser, H
    DelemarrevandeWaal, H
    Jansen, M
    Drop, S
    CLINICAL ENDOCRINOLOGY, 1997, 46 (04) : 451 - 459
  • [3] Growth hormone treatment regimens in girls with Turner syndrome
    Keizer-Schrama, SMPFD
    Sas, TCJ
    ACTA PAEDIATRICA, 1999, 88 : 126 - 129
  • [4] Psychosocial functioning after discontinuation of long-term growth hormone treatment in girls with Turner syndrome
    van Pareren, YK
    Duivenvoorden, HJ
    Slijper, FME
    Koot, HM
    Drop, SLS
    Keizer-Schrama, SMPFD
    HORMONE RESEARCH, 2005, 63 (05) : 238 - 244
  • [5] A decade of growth hormone treatment in girls with Turner syndrome in the UK
    Betts, PR
    Butler, GE
    Donaldson, MDC
    Dunger, DB
    Johnston, DI
    Kelnar, CJH
    Kirk, J
    Price, DA
    Wilton, P
    ARCHIVES OF DISEASE IN CHILDHOOD, 1999, 80 (03) : 221 - 225
  • [6] Carbohydrate and lipid metabolism during various growth hormone dosing regimens in girls with Turner syndrome
    van Teunenbroek, A
    Keizer-Schrama, SMPFD
    Aanstoot, HJ
    Stijnen, T
    Hoogerbrugge, N
    Drop, SLS
    METABOLISM-CLINICAL AND EXPERIMENTAL, 1999, 48 (01): : 7 - 14
  • [7] Effect of discontinuation of long-term growth hormone treatment on carbohydrate metabolism and risk factors for cardiovascular disease in girls with Turner syndrome
    van Pareren, YK
    Keizer-Schrama, SMPFD
    Stijnen, T
    Sas, TCJ
    Drop, SLS
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2002, 87 (12): : 5442 - 5448
  • [8] Prediction of Response to Growth Hormone Treatment in Korean Girls with Turner Syndrome
    Jung, Mo Kyung
    Kim, Se Young
    Lee, Ji-Eun
    Kim, Hae Soon
    Yu, Jeesuk
    Yoo, Eun-Gyong
    HORMONE RESEARCH IN PAEDIATRICS, 2018, 90 : 467 - 467
  • [9] Carbohydrate metabolism during long-term growth hormone (GH) treatment and after discontinuation of GH treatment in girls with turner syndrome participating in a randomized dose-response study
    Sas, TCJ
    Keizer-Schrama, SMPFD
    Stijnen, T
    Aanstoot, HJ
    Drop, SLS
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2000, 85 (02): : 769 - 775
  • [10] Growth hormone (GH) treatment reduces peripheral thyroid hormone action in girls with Turner syndrome
    Susperreguy, S.
    Miras, M. B.
    Montesinos, M. M.
    Mascanfroni, I. D.
    Munoz, L.
    Sobrero, G.
    Silvano, L.
    Masini-Repiso, A. M.
    Coleoni, A. H.
    Targovnik, H. M.
    Pellizas, C. G.
    CLINICAL ENDOCRINOLOGY, 2007, 67 (04) : 629 - 636